ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add three multiple ascending dose (MAD) cohorts and an additional single ascending high dose (SAD) cohort to the trial.

“The revised trial design amendment will enable us to expeditiously execute the SAD and MAD parts of this Phase 1 clinical trial and obtain important PK-PD, safety and tolerability data that will inform future Phase 2 clinical trial protocols addressing our target indications,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “We look forward to providing additional updates on the trial and obtaining data from this study as it progresses and continues to support our other programs.”

Prior to the amendment, the Phase 1 trial was a single ascending dose randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK and PD of RLS-0071 in healthy subjects.

State public health laboratory, Henrico County Schools launch pilot program to promote life science career

More than 50 Henrico County high school students and teachers joined scientists from Virginia’s public health and environmental laboratory Wednesday to kick off an innovative program that brings together private and government scientists and experts, business and nonprofit leaders, and public schools to explore ways to create a pipeline of talent to fuel Virginia’s growing …

09/21/2023

Climate Tech Startup ThermaGEL Innovations’ Breakthrough Aerogels Join the Challenge to Save Half-Gigaton of C02 Emissions Each Year

In the fight against climate change, properly insulating homes and buildings can significantly raise energy efficiency and indoor air quality while lowering carbon dioxide emissions. A startup company, spun out of research at Virginia Commonwealth University, is commercializing what it calls a breakthrough in low-cost insulation materials. ThermaGEL Innovations has developed insulation material using aerogels, …

09/20/2023

Charlottesville healthy sugar innovator Bonumose raises $2M

Bonumose Inc., a Charlottesville startup specializing in table sugar alternatives, has raised $2 million toward a $10 million funding round after German flavor and fragrances producer Symrise AG signed a minority investment agreement with the company. “The strategic investment from Symrise is part of a larger funding round that will be used for increasing sales, …

News